Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07218809 · ClinicalTrials.gov registry record · Phase 3
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
A Phase 3 study of Epithelial Ovarian Cancer, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,100
- Enrollment target
- 20
- Study locations
NCT07218809 is a Phase 3 study of Epithelial Ovarian Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 1,100 participants, above the 184-participant average among 41 other Epithelial Ovarian Cancer trials with a reported enrollment target (498% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT07218809, a Phase 3 study of Epithelial Ovarian Cancer, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, expressing high or low FRα levels.
Conditions Studied
Interventions
- DRUG AZD5335
- DRUG Paclitaxel
- DRUG Mirvetuximab Soravtansine (MIRV)
- DRUG Pegylated liposomal Doxorubicin (PLD)
- DRUG Topotecan
Study Locations (20)
Illinois
- Research Site - Evanston
- Research Site - Peoria
- Research Site - Urbana
Other
- Research Site - Adelaide
- Research Site - Auchenflower
- Research Site - Box Hill
Florida
- Research Site - Fort Lauderdale
- Research Site - Jupiter
Massachusetts
- Research Site - Burlington
- Research Site - Worcester
Ohio
- Research Site - Dayton
- Research Site - Sylvania
Texas
- Research Site - San Antonio
- Research Site - Tyler
Maryland
- Research Site - Towson
Minnesota
- Research Site - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,100 participants |
| Start Date | 2025-12-29 |
| Est. Completion | 2030-05-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07218809
The ClinicalTrials.gov registry entry for NCT07218809 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,100 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 184-participant average among 41 other Epithelial Ovarian Cancer trials with a reported enrollment target (498% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Epithelial Ovarian Cancer appearing as the primary indexed condition, and to 5 interventions - of which AZD5335 is the first listed.
NCT07218809 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Illinois, Other, Florida.
Frequently Asked Questions
What is clinical trial NCT07218809 about?
NCT07218809 is a clinical study titled "AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer". The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, expressing high or low FRα levels.
What is the current status of trial NCT07218809?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,100 participants. The study started on 2025-12-29. Estimated completion is 2030-05-27.
What conditions does trial NCT07218809 study?
This clinical trial studies the following conditions: Epithelial Ovarian Cancer.
What interventions are being tested in trial NCT07218809?
The interventions under investigation include: AZD5335 (DRUG), Paclitaxel (DRUG), Mirvetuximab Soravtansine (MIRV) (DRUG), Pegylated liposomal Doxorubicin (PLD) (DRUG), Topotecan (DRUG).
Who is sponsoring clinical trial NCT07218809?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07218809 being conducted?
This trial has 20 study locations across Florida, Illinois, Maryland, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epithelial Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 3
-
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
COMPLETED · Phase 3
-
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
COMPLETED · Phase 3
-
T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.